{Reference Type}: Observational Study
{Title}: Prostate health index (PHI) as an accurate prostate cancer predictor.
{Author}: Yáñez-Castillo YM;Melgarejo-Segura MT;Funes-Padilla C;Folgueral-Corral ME;García-Larios JV;Arrabal-Polo MA;De Haro Muñoz T;Arrabal-Martín M;
{Journal}: J Cancer Res Clin Oncol
{Volume}: 149
{Issue}: 11
{Year}: 2023 Sep 19
{Factor}: 4.322
{DOI}: 10.1007/s00432-023-04860-6
{Abstract}: <B>OBJECTIVE: </B>This study aims to compare the ability of the PHI versus tPSA test to predict the presence of PCa in our population.<BR><B>METHODS: </B>A prospective observational study was performed. We included patients with tPSA ≥ 2.5 ng/ml, biopsy naïve or previous negative biopsy, undergoing a blood test, which includes tPSA, fPSA, and p2PSA, and a prostate biopsy between March 2019 and March 2022. Patients with PCa found in the biopsy-Group A-were compared with patients with a negative biopsy result-Group B. Diagnostic accuracy of tPSA and PHI was assessed by receiver operating characteristic [ROC] curves and logistic regression.<BR><B>RESULTS: </B>140 men were included. Fifty-seven (40.7%) had a positive prostate biopsy result (Group A), and 83 (59.3%) had a negative biopsy result (Group B). The mean age was similar in both groups (mean ± standard deviation), 66.86 ± 6.61 years. No difference was found in the tPSA value between the groups (Group A PSA: 6.11 ng/ml (3.56-17.01); Group B: 6.42 ng/ml (2.46-19.45), p = 0.41). The mean value of PHI was statistically different between groups (Group A 65.50 (29-146) vs. Group B 48 (16-233), p = 0.0001). The area under the curve 0.44 for tPSA and 0.77 for PHI. The multivariate logistic regression model applied to PHI showed a significant increase in its predictive accuracy: 72.14% in the model without PHI, 76.09% with PHI.<BR><B>CONCLUSIONS: </B>The PHI test improves PCa detection compared to tPSA in our population.